Sentences with phrase «tumors in mice with»

Scientists exploit gene therapy to shrink tumors in mice with an aggressive form of breast cancer.

Not exact matches

While study results indicated that combining capsaicin with the chemicals «might promote cancer cell survival,» the report clearly stated that the control group of mice treated only with capsaicin ``... did not induce any skin tumors...» In addition, the study repeatedly cited other research studies in which the anti-cancer properties of capsaicin were solidly demonstrateIn addition, the study repeatedly cited other research studies in which the anti-cancer properties of capsaicin were solidly demonstratein which the anti-cancer properties of capsaicin were solidly demonstrated.

In contrast, treatment with only capsaicin or vehicle did not induce any skin tumors in either TRPV1 / WT or KO mice (Table 1; Fig. 1C), indicating that capsaicin alone does not act as a carcinogeIn contrast, treatment with only capsaicin or vehicle did not induce any skin tumors in either TRPV1 / WT or KO mice (Table 1; Fig. 1C), indicating that capsaicin alone does not act as a carcinogein either TRPV1 / WT or KO mice (Table 1; Fig. 1C), indicating that capsaicin alone does not act as a carcinogen.

Mouse tumors injected directly with the reprogrammed stem cells shrank 20 - to 50-fold in 24 — 28 days compared with nontreated mice.

«Indeed, in a second tumor model of metastatic breast cancer, we demonstrated that mice treated with the EphA2 - targeting paclitaxel conjugate presented nearly no lung metastases, while a large numbers of lesions were observed in both untreated mice and in mice treated with just paclitaxel.»

In the upper panel, tumor cells formed colonization at day 14, while in the lower panel, when the mouse was treated with the compound edelfosine, most of the tumor cells disappeared at day 10 and failed to form colonization at day 1In the upper panel, tumor cells formed colonization at day 14, while in the lower panel, when the mouse was treated with the compound edelfosine, most of the tumor cells disappeared at day 10 and failed to form colonization at day 1in the lower panel, when the mouse was treated with the compound edelfosine, most of the tumor cells disappeared at day 10 and failed to form colonization at day 14.

On its own, this immune response had no immediate effect in the fight against the utilized breast tumors, but in combination with the ADC it proved itself effective in attacking cancer cells in mice, resulting in the complete cure of the majority of mice receiving the combination therapy.

A combination of fostamatinib and paclitaxel reduced tumor size in six mice by up to 87 percent, compared with no shrinkage in six untreated animals after three weeks.

After five weeks, the combination treatment in the six mice decreased tumor size by up to 66 percent, compared with six mice treated with only paclitaxel.

To confirm this synergistic effect, the team measured serum levels of signaling proteins in tumor - bearing mice receiving OX40 agonist antibodies alone or in combination with GSK2636771.

Shih, Wang and their colleagues tested fostamatinib's power to reduce tumor size in mice implanted with human ovarian cancer cells that were resistant to paclitaxel.

Researchers used tissue and blood samples to show that the gammopathy (a precursor to myeloma) in both mice and patients with Gaucher disease is triggered by specific lipids, and that the antibodies made by tumor cells in nearly a third of myeloma patients are directed against such lipids.

In the Cell study, Dr. Massagué, with Fellow Manuel Valiente, PhD, and other team members, found that in mouse models of breast and lung cancer — two tumor types that often spread to the brain — many cancer cells that enter the brain are killed by astrocyteIn the Cell study, Dr. Massagué, with Fellow Manuel Valiente, PhD, and other team members, found that in mouse models of breast and lung cancer — two tumor types that often spread to the brain — many cancer cells that enter the brain are killed by astrocytein mouse models of breast and lung cancer — two tumor types that often spread to the brain — many cancer cells that enter the brain are killed by astrocytes.

Northwestern Medicine scientists have identified a small RNA molecule called miR - 182 that can suppress cancer - causing genes in mice with glioblastoma mulitforme (GBM), a deadly and incurable type of brain tumor.

The study, published online April 16 in Nature Medicine, represents the first time a severe brainstem cancer, diffuse intrinsic pontine glioma, has been eradicated in mice with the tumor.

«It's very difficult to produce a mouse model of a solid tumor of the type we see in most women who are diagnosed with cervical cancer.

The investigators report that trapping virus - loaded stem cells in a gel and applying them to tumors significantly improved survival in mice with glioblastoma multiforme, the most common brain tumor in human adults and also the most difficult to treat.

In addition, they injected mice with human cancer cells and found that the tumors grown in mice could be inhibited with PD17307In addition, they injected mice with human cancer cells and found that the tumors grown in mice could be inhibited with PD17307in mice could be inhibited with PD173074.

Next, the team tested the GD2 CAR - T cells in mice whose brainstem was implanted with human DIPG tumors, an experimental system that Monje's lab pioneered.

The research team also tried the GD2 CAR - T therapy in mice with human spinal cord and thalamic tumors implanted in their respective anatomical locations.

The researchers confirmed these findings in a mammary carcinoma mouse model — treatment with dasatinib just a few days after administering two high doses of chemotherapy prevented tumor growth and increased survival rates.

When injected with cancer cells, animals housed there developed tumors 80 % smaller than those in control mice, or no tumors at all.

In mice, the Runx2 knock - in myeloma cells produced greater tumor growth and a wider spread of disease compared with the original myeloma cells; conversely, the Runx2 knock - down cells had less tumor growth and disease spreaIn mice, the Runx2 knock - in myeloma cells produced greater tumor growth and a wider spread of disease compared with the original myeloma cells; conversely, the Runx2 knock - down cells had less tumor growth and disease spreain myeloma cells produced greater tumor growth and a wider spread of disease compared with the original myeloma cells; conversely, the Runx2 knock - down cells had less tumor growth and disease spread.

Researchers have isolated exosomes from tumors and from blood of patients with breast cancer, and from blood of mice with human tumors grown after breast implantation in mice, called ortoxenogratfs.

«Despite the low infection levels of mouse cells with oHSV, we were able to cause a delay in tumor growth in one of the cancer models and even cure many of the mice in a second model,» said first author Jennifer Leddon, who conducted much of the laboratory work during a research experience in the Center for Childhood Cancer and Blood Diseases.

They have also, in experiments with mice, been able to slow eye tumor growth with an existing FDA - approved drug.

Compared to a control (left), epalrestat treatment (right) reduces the number of metastatic tumors (arrowheads) in the lungs of mice injected with human basal - like breast cancer cells.

Dr. Cripe and his colleagues at The Ohio State University, the University of Pittsburgh School of Medicine and Cincinnati Children's Hospital Medical Center tested how well the oncolytic viral therapy — a cancer - killing form of the herpes simplex virus, called oHSV — infected and killed tumor cells in mice with and without a healthy immune system.

In one experiment, 26 of 50 well - fed mice developed mammary tumors after two years, compared with zero of 50 that were allowed only enough food to keep them going.

Much of the cancer - killing effect of the oHSV injections was lost when the researchers tested the therapy in tumors of mice with defective immune systems.

In mice with pancreatic tumors, Kalbasi and other members of the team found relatively high levels of inflammatory compounds including CCL2, the signaling molecule that activates CCR2 on monocytes and macrophages to make these cells migrate to tumors.

The common pathway found in mouse models was also found in human tumors, suggesting that resistance could indeed be blocked in patients with the same drug as in mice.

In experiments with mice, the UC San Diego - led team showed that verteporfin also suppresses the growth of uveal melanoma tumors derived from human tumors.

In collaboration with the group of Valerian Kagan, Ph.D., D.Sc., at the University of Pittsburgh, Gabrilovich and colleagues analyzed in great detail the events that take place in the DCs from tumor - bearing mice models and found that impaired cross-presentation, which occurred in the presence of tumor - derived factors, was associated with defective trafficking of the antigen - MHC complex to the cell surfacIn collaboration with the group of Valerian Kagan, Ph.D., D.Sc., at the University of Pittsburgh, Gabrilovich and colleagues analyzed in great detail the events that take place in the DCs from tumor - bearing mice models and found that impaired cross-presentation, which occurred in the presence of tumor - derived factors, was associated with defective trafficking of the antigen - MHC complex to the cell surfacin great detail the events that take place in the DCs from tumor - bearing mice models and found that impaired cross-presentation, which occurred in the presence of tumor - derived factors, was associated with defective trafficking of the antigen - MHC complex to the cell surfacin the DCs from tumor - bearing mice models and found that impaired cross-presentation, which occurred in the presence of tumor - derived factors, was associated with defective trafficking of the antigen - MHC complex to the cell surfacin the presence of tumor - derived factors, was associated with defective trafficking of the antigen - MHC complex to the cell surface.

In a mouse model of triple - negative breast cancer, mice injected with cancer cells that over-express ZMYND11 had tumor volumes of less than 50 cubic millimeters while control mice and those injected with cells expressing ZMYND11 deficient for binding to the methyl group had tumor volumes ranging from 150 to 400 cubic millimeters at eight weeks.

In a new study, a team found that injecting mice with tiny magnets and cranking up the heat eliminated tumors from the animals» bodies with no apparent side effects.

Desgrosellier said the team will follow up with mouse models containing tumor fragments from patients to better reflect the diversity of cell types present in human disease.

Mice with cancer were placed in an alternating magnetic field, causing nanoparticles injected into a tumor to give out heat and destroy it.

Mice engineered to express Lin28 in their kidneys developed Wilms tumor, which regressed when Lin28 was withdrawn, indicating that strategies aimed at blocking or deactivating the gene hold therapeutic promise for children with Wilms.

Moreover, this approach was effective in treating mice with malignant colorectal cancer tumors containing Kras and p53 mutations, which are found in about half of colorectal tumors in humans.

Unaltered cells created tumors in all seven mice injected with such cells, but when cells missing ALKBH5 were used, they caused tumors in only 43 percent (six out of 14) of mice.

This technique is able to distinguish cancer cell lines with differing metabolic activities and reveals heterogeneous uptake patterns in neurons, mouse brain tissues and tumor tissues with clear cell - to - cell variations.

Now, thanks to the new mouse model, it will be possible to study how renal tumors are able to develop in an environment with a normal immune system, and how cancer cells manage to evade the immune system's attacks.

The tumors in Sand's lab might be explained by the high dose, the fact that the mice were newborns, and the type of mouse, suggests Kay, who was involved with a past clinical trial administering AAV to the liver to treat hemophilia.

The researchers showed in mouse models that chronic skin inflammation caused by continuous skin contact with allergens contributes to tumor development.

In this mouse model, mutations in Kras and p53 genes resulted in the formation of individual tumor cell populations that were labeled with different colorIn this mouse model, mutations in Kras and p53 genes resulted in the formation of individual tumor cell populations that were labeled with different colorin Kras and p53 genes resulted in the formation of individual tumor cell populations that were labeled with different colorin the formation of individual tumor cell populations that were labeled with different colors.

That's the nodule type of tumor we saw in the mice with the silenced protein,» said Douglas Kniss, professor of obstetrics and gynecology at Ohio State's Wexner Medical Center and senior author of the study.

And in 2001, molecular biologist Mark Sands at Washington University in St. Louis, Missouri, found a high rate of liver tumors in middle - aged mice that had been treated as newborns with a supposedly safer viral vector.

Tumor size in mice injected with the antibody steadily decreased over time, while their survival increased.

We created a mouse xenograft model in which SiHa cervical cancer cells were injected into mice subcutaneously, and the resultant tumors were treated with PAL three times a week for 6 weeks.